CVS outlines separation in H1 2028 and projects at least $8.65 adjusted EPS in 2027 (NYSE:CVS)
CVS Health (CVS) plans to split into two publicly traded companies by H1 2028. The remaining healthcare solutions company will include Aetna, Caremark, and other units. The company projects at least $8.65 adjusted EPS for 2027, according to its Q3 2026 earnings call.
How this was made
The 30-second read
Why it matters
The split creates two distinct investment stories, while the EPS guidance of $8.65 for 2027 sets expectations for the insurance side.
Market read
A major structural change for a large‑cap health‑care player, likely to affect valuation models and sector positioning.
What to watch
Potential cost synergies from the separation and the impact of upcoming Medicare policy changes on the insurance arm.
Background
CVS Health disclosed its intention to separate into two publicly traded entities, retaining Aetna, Caremark, pharmacy services, specialty pharmacy, Oak Street, and Signify Health in the health‑care solutions company.
Ticker impact
CVS announced a planned split into two independent public companies and provided adjusted EPS guidance of at least $8.65 for 2027.
potential downside as the market prices in the separation and modest EPS outlook
The announcement is the first public disclosure of the split and new guidance, a material event for a large‑cap health‑care stock.
Market effects
May prompt re‑rating of health‑care services and pharmacy segments as investors separate the insurance and pharmacy businesses.
U.S. health‑care sector could see modest volatility; limited impact outside North America.
Limited to investors with exposure to U.S. health‑care stocks; no broad macro effect.
Counterpoint
The split could unlock value if the pharmacy business outperforms expectations, leading to upside beyond the short‑term pressure.
Key entities
- CompanyCVS Health
U.S. health‑care services and pharmacy retailer.
